We are live on ! Find out more
EW icon

Edwards Lifesciences

1,253 hedge funds and large institutions have $38.2B invested in Edwards Lifesciences in 2025 Q3 according to their latest regulatory filings, with 113 funds opening new positions, 444 increasing their positions, 443 reducing their positions, and 106 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more first-time investments, than exits

New positions opened: 113 | Existing positions closed: 106

0% more repeat investments, than reductions

Existing positions increased: 444 | Existing positions reduced: 443

0% more funds holding in top 10

Funds holding in top 10: 1010 (0)

0% less funds holding

Funds holding: 1,2591,253 (-6)

3% less capital invested

Capital invested by funds: $39.4B → $38.2B (-$1.2B)

1.96% less ownership

Funds ownership: 85.71%83.75% (-2%)

13% less call options, than puts

Call options by funds: $295M | Put options by funds: $337M

Holders
1,253
Holders Change
-6
Holders Change %
-0.48%
% of All Funds
16.44%
Holding in Top 10
10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.13%
New
113
Increased
444
Reduced
443
Closed
106
Calls
$295M
Puts
$337M
Net Calls
-$42.4M
Net Calls Change
-$147M
Name Holding Trade Value Shares
Change
Change in
Stake
Pacer Advisors
351
Pacer Advisors
Pennsylvania
$3.76M -$94.7K -1,212 -2%
PAS
352
Point72 Asia (Singapore)
Singapore
$3.72M +$3.08M +39,404 +470%
WSCM
353
Wellington Shields Capital Management
New York
$3.7M -$117K -1,500 -3%
OSAM
354
O'Shaughnessy Asset Management
Connecticut
$3.69M +$255K +3,264 +7%
LGF
355
LGT Group Foundation
Liechtenstein
$3.68M -$235K -3,007 -6%
MWM
356
Mission Wealth Management
California
$3.65M +$108K +1,377 +3%
WCG
357
Weaver Consulting Group
California
$3.61M -$781 -10 -0%
BHCM
358
Brevan Howard Capital Management
Jersey
$3.6M -$2.59M -33,100 -42%
SC
359
Stance Capital
Massachusetts
$3.58M +$2.83M +36,272 +373%
BBI
360
Baxter Bros Inc
Connecticut
$3.54M -$283K -3,625 -7%
BAMF
361
BI Asset Management Fondsmaeglerselskab
Denmark
$3.51M +$1.52M +19,506 +76%
Osaic Holdings
362
Osaic Holdings
Arizona
$3.5M +$172K +2,196 +5%
MSU
363
Mizuho Securities USA
New York
$3.48M +$173K +2,216 +5%
EI
364
Ethic Inc
New York
$3.47M -$786K -10,056 -18%
OAC
365
OMERS Administration Corp
Ontario, Canada
$3.46M
STA
366
Summit Trail Advisors
New York
$3.36M +$552K +7,064 +20%
KWM
367
Kingsview Wealth Management
Oregon
$3.31M +$1.34M +17,188 +68%
MPWS
368
McCarter Private Wealth Services
Massachusetts
$3.29M -$58.8K -752 -2%
FNA
369
First National Advisers
Nebraska
$3.28M +$51.9K +664 +2%
BCM
370
Bayesian Capital Management
New York
$3.27M +$3.29M +42,100 New
BC
371
Burney Company
Virginia
$3.15M +$309K +3,960 +11%
GAM
372
Generali Asset Management
Italy
$3.14M +$97.2K +1,244 +3%
APG
373
Abacus Planning Group
South Carolina
$3.12M
FFA
374
First Foundation Advisors
California
$3.09M +$36.8K +471 +1%
FNBOO
375
First National Bank of Omaha
Nebraska
$3.07M -$150K -1,923 -5%

EW Hedge Fund Activity: Q3 2025 in Review

1,253 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q3 2025, worth a combined $38.2B — down 3% from $39.4B a quarter earlier.

Buyers outnumbered sellers: 113 funds opened new EW positions and 106 closed out — a net gain of 7 holders — while 444 added to existing stakes and 443 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $942M. The largest seller was Citadel Advisors, cutting an estimated $664M.

  • 1,253 institutional investors held Edwards Lifesciences (EW) as of Q3 2025, down from 1,259 in Q2 2025.
  • Funds reported $38.2B of Edwards Lifesciences stock for Q3 2025, down 3% quarter-over-quarter.
  • 113 funds opened new Edwards Lifesciences positions in Q3 2025 and 106 closed out, a net change of +7 holders.
  • The largest Edwards Lifesciences buyer in Q3 2025 was Fidelity Investments, an estimated $942M added.
  • The largest Edwards Lifesciences seller in Q3 2025 was Citadel Advisors, an estimated $664M sold.

Based on aggregated 13F filings for Q3 2025.